4.5 Article

Aβ oligomers induce pathophysiological mGluR5 signaling in Alzheimer's disease model mice in a sex-selective manner

期刊

SCIENCE SIGNALING
卷 13, 期 662, 页码 -

出版社

AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scisignal.abd2494

关键词

-

资金

  1. Canadian Institutes for Health Research (CIHR) [PJT-148656, PJT-165967]
  2. Krembil Foundation
  3. University of Ottawa
  4. Shanghai Institute of Materia Medica (SIMM-uOttawa) Joint Research Center
  5. Alberta Innovates Health Solutions (AIHS)
  6. CIHR

向作者/读者索取更多资源

The prevalence, presentation, and progression of Alzheimer's disease (AD) differ between men and women, although beta-amyloid (A beta) deposition is a pathological hallmark of AD in both sexes. A beta-induced activation of the neuronal glutamate receptor mGluR5 is linked to AD progression. However, we found that mGluR5 exhibits distinct sex-dependent profiles. Specifically, mGluR5 isolated from male mouse cortical and hippocampal tissues bound with high affinity to A beta oligomers, whereas mGluR5 from female mice exhibited no such affinity. This sex-selective A beta-mGluR5 interaction did not appear to depend on estrogen, but rather AD interaction with cellular prion protein (PrPC), which was detected only in male mouse brain homogenates. The ternary complex between mGluR5, A beta oligomers, and PrPC was essential to elicit mGluR5-dependent pathological suppression of autophagy in primary neuronal cultures. Pharmacological inhibition of mGluR5 reactivated autophagy, mitigated A beta pathology, and reversed cognitive decline in male APPswe/PS1 Delta E9 mice, but not in their female counterparts. A beta oligomers also bound with high affinity to human mGluR5 isolated from postmortem donor male cortical brain tissue, but not that from female samples, suggesting that this mechanism may be relevant to patients. Our findings indicate that mGluR5 does not contribute to A beta pathology in females, highlighting the complexity of mGluR5 pharmacology and A beta signaling that supports the need for sex-specific stratification in clinical trials assessing AD therapeutics.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据